CDT Equity (CDT) Stock Price, News & Analysis

Company Overview

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

Key Stats

• Today's Range: $2.90 to $3.32
• 50-Day Range: $2.55 to $15.00
• 52-Week Range: $2.53 to $3,800.00
• Volume: 57,622 shs
• Average Volume: 307,611 shs
• Market Capitalization: $1.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

CDT Equity Stock Analysis - MarketRank™

CDT Equity scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

CDT Equity has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

CDT Equity has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of CDT Equity is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CDT Equity is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

42.70% of the float of CDT Equity has been sold short.

Short Interest Ratio / Days to Cover

CDT Equity has a short interest ratio ("days to cover") of 0.49, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CDT Equity has recently increased by 10.52%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CDT Equity does not currently pay a dividend.

Dividend Growth

CDT Equity does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.48

News Sentiment

CDT Equity has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for CDT Equity this week, compared to 2 articles on an average week.

MarketBeat Follows

Only 1 people have added CDT Equity to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CDT Equity insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.78% of the stock of CDT Equity is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

3.29% of the stock of CDT Equity is held by institutions.

Company Calendar

• Last Earnings: 7/15/2026
• Today: 8/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CDT
• Previous Symbol: NASDAQ:CDT
• CIK: 1896212
• Web: www.conduitpharma.com
• Phone: 760-471-8536
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($14,265.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$39.22 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -145.29%
• Return on Assets: -103.25%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.14
• Quick Ratio: 0.14

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($778.17) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 490,000
• Free Float: 434,000
• Market Cap: $1.58 million
• Optionable: Not Optionable
• Beta: 1.52